Scarica l'app Stockscreener
9.20
0.88%
0.08
Pre-mercato:
9.35
0.15
+1.63%
Precedente Chiudi:
$9.12
Aprire:
$9.01
Volume 24 ore:
3.16M
Relative Volume:
0.89
Capitalizzazione di mercato:
$1.02B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-4.5545
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
+6.60%
1M Prestazione:
+12.75%
6M Prestazione:
-31.03%
1 anno Prestazione:
-65.14%
Intervallo 1D:
$8.70
$9.25
Intervallo di 1 settimana:
$8.33
$10.15
Portata 52W:
$6.78
$26.18
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
9.20 | 1.06B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
241.60 | 39.03B | 2.75B | 714.14M | 1.09B | 4.33 |
|
TEM
Tempus Ai Inc
|
62.60 | 11.29B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
97.65 | 7.90B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
58.45 | 11.14B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
39.25 | 7.01B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker - Stock Titan
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | T - GuruFocus
Analyst Expectations For 10x Genomics's Future - Benzinga
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
JPMorgan Chase & Co. Cuts 10x Genomics (NASDAQ:TXG) Price Target to $9.00 - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
10x Genomics (NASDAQ:TXG) Shares Gap Up – Time to Buy? - Defense World
10x Genomics (NASDAQ:TXG) Receives Sell (E+) Rating from Weiss Ratings - Defense World
10x Genomics First Quarter 2025 Earnings: Beats Expectations - simplywall.st
30,005 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Raymond James Financial Inc. - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Q1 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target for 10x Genomics (TXG) Amid Market Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Lowered to $9 by JP Morgan | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain O - GuruFocus
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Conc - GuruFocus
Deutsche Bank Adjusts Price Target on 10x Genomics to $10 From $16, Maintains Hold Rating - marketscreener.com
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain Outlook | TXG Stock News - GuruFocus
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics (NASDAQ:TXG) adds US$65m to market cap in the past 7 days, though investors from five years ago are still down 89% - simplywall.st
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics Reports First Quarter 2025 Financial Results - BioSpace
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - GuruFocus
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance - Benzinga
10x Genomics: Q1 Earnings Snapshot - CTPost
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations - Yahoo Finance
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Announces Workforce Reduction to Cut Costs - TipRanks
10x Genomics Inc Q1 2025 Earnings: EPS of -$0.28 Beats Estimate, Revenue Surges to $154.9 Million - GuruFocus
Earnings Flash (TXG) 10x Genomics Posts Q1 Loss $-0.28 Per Share, vs. FactSet Est of $-0.47 - marketscreener.com
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago - Yahoo Finance
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10 X Genomics Inc Azioni (TXG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Feb 28 '25 |
Sale |
10.63 |
7,942 |
84,393 |
871,540 |
1.68%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):